| NCT ID | NCT03910465 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute (NCI) |
| Condition | Chordoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2019-04-16 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2019-04-16 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Chordoma is a rare type of bone cancer. It occurs in the skull base or spine. Researchers want to study people with chordoma in different ways. They hope this will help them design better future treatments and supportive care studies for this disease. Objective: To learn more about chordoma by looking at its clinical course, how it appears on imagine scans, and how it responds to therapies and treatments. Eligibility: People ages 2 and older with chordoma who are enrolled in NCI protocol 19-C-0016 Design: Participants will be screened with their medical history. Participants will have a visit to examine their disease. This will include: * Physical exam * Neurologic exam * CT scan and MRI: Participants will lie on a table. The table will slide into a machine. The machine will take pictures of the body. Participants will have other tests every 6-12 months: * Smell test * Surveys to assess their emotional, physical, and behavioral well-being and needs * Cognitive function tests Participants or their home doctors will be contacted every 6 12 months. They will be asked to provide information about their disease. This could include test results and imaging evaluations. Some participants may be asked to come to the clinic for more visits.
Eligibility Criteria
* INCLUSION CRITERIA: * Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written consent document. * Subjects with radiographically or histologically documented chordoma * Age \>= 2 years old * Subjects must be enrolled into NCI protocol 19-C-0016: "Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors". EXCLUSION CRITERIA: -None
Contact & Investigator
Mary F Wedekind Malone, D.O.
PRINCIPAL INVESTIGATOR
National Cancer Institute (NCI)
Frequently Asked Questions
Who can join the NCT03910465 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, studying Chordoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03910465 currently recruiting?
Yes, NCT03910465 is actively recruiting participants. Contact the research team at barbara.thomas2@nih.gov for enrollment information.
Where is the NCT03910465 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT03910465 clinical trial?
NCT03910465 is sponsored by National Cancer Institute (NCI). The principal investigator is Mary F Wedekind Malone, D.O. at National Cancer Institute (NCI). The trial plans to enroll 300 participants.